Cardiac injury remains a major cause of morbidity and mortality worldwide. Despite
significant advances, a full understanding of why the heart fails to fully recover function after …

Cardiovascular diseases remain the leading cause of death worldwide, with pathological
fibrotic remodeling mediated by activated cardiac myofibroblasts representing a unifying …

In heart failure with preserved ejection fraction (HFpEF), the occurrence of myocardial
fibrosis is associated with adverse outcome. Whether pirfenidone, an oral antifibrotic agent …

Fibrosis is a pivotal player in heart failure development and progression. Measurements of
(markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with …

Our understanding of the functions of cardiac fibroblasts has moved beyond their roles in
heart structure and extracellular matrix generation and now includes their contributions to …

Myocardial fibrosis is a remodeling process of the extracellular matrix (ECM) following
cardiac stress.“Replacement fibrosis” is a term used to describe wound healing in the acute …

While interstitial fibrosis plays a significant role in heart failure, our understanding of disease
progression in humans is limited. To address this limitation, we have engineered a cardiac …

Pirfenidone is an orally active small molecule that has recently been evaluated in large
clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the …

Cardiovascular disease is a leading cause of mortality in the world and is exacerbated by
the presence of cardiac fibrosis, defined by the accumulation of noncontractile extracellular …

Transforming growth factor-β (TGF-β) is a common mediator of cancer progression and
fibrosis. Fibrosis can be a significant pathology in multiple organs, including the heart. In this …